Double-blind placebo-controlled immunotherapy with mixed grass-pollen allergoids

Bousquet, Jean; Maasch, H.J.; Martinot, B.; Hejjaoui, A.; Wahl, R.; Michel, François‐Bernard

doi:10.1016/0091-6749(88)90017-6

Cited by 156 publications

(18 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is probably due to the fact that the majority of allergic patients diagnosed and followed up at the various allergy centers are young, and that in most cases older patients have long-lasting diseases that are unlikely to respond to desensitizing treatment [5, 6]. Nonetheless, in a study carried out in Florida, otherwise healthy patients >60 years and controls <60 years showed a similar, favorable response to SIT, suggesting that age alone should not be a decision factor in the initiation of SIT in the elderly [13]; unfortunately, in that study disease duration was not reported.…”

Section: Discussionmentioning

confidence: 99%

“…Injection allergen-specific immunotherapy (SIT) is an established means for the treatment of airborne allergies; its efficacy and long-term effect in reducing allergic symptoms have been shown by a number of studies [1, 2, 3, 4, 5]. However, whether SIT may be considered as a therapeutic option also in older patients is still debated.…”

Section: Introductionmentioning

confidence: 99%

“…However, whether SIT may be considered as a therapeutic option also in older patients is still debated. Position papers by the World Health Organization and the European Academy of Allergology and Clinical Immunology suggest that SIT should be started early in the disease process [1, 2]as the clinical response to the treatment in patients showing chronic, irreversible changes of the airways is poor [5, 6]. As a consequence, older patients with long-standing allergic disorders have been excluded from most studies of immunotherapy, and SIT is generally not considered a therapeutic option in these subjects.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of Injection Immunotherapy with Ragweed and Birch Pollen in Elderly Patients

Asero¹

2004

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: The role of specific immunotherapy (SIT) in elderly allergic patients is still debated. Objective: The aim of this study was to assess whether SIT is associated with a better control of symptoms and a better quality of life also in older allergic patients. Methods: The effect of injection SIT was assessed in 39 patients [age >54 years, median 59; 29 patients (74%) with asthma, otherwise healthy] monosensitized to birch (n = 20) and ragweed (n = 19). Thirty-three younger subjects [age <50 years, median 35; 26 patients (79%) with asthma, otherwise healthy] monosensitized to birch (n = 10) and ragweed (n = 23), and 37 subjects >54 years old (25 males/12 females; age 55–79 years, median 59 years) monosensitized to birch (n = 18) and ragweed (n = 19) who refused to undergo SIT were enrolled as positive and negative controls, respectively. All groups had a disease duration <10 years; the disease was inadequately controlled with standard drug therapies in all cases. SIT was carried out using the same extracts and was administered using a perennial schedule both in patients and controls. Seasonal therapies were the same in all groups and were not changed after SIT was started. After 1–5 years of SIT, patients and controls were asked to quantify symptom reduction on a visual analogue scale: reductions >50% were considered significant. Moreover, the use of cetirizine and/or salbutamol as an adjunct to standard therapies during the last pollen season was assessed as an objective measure of SIT outcome. Results: 37/39 (95%) patients versus 32/33 (97%) controls submitted to SIT reported a symptom reduction >50% after 1–5 years of SIT (nonsignificant). The median clinical efficacy of SIT was 80% in both groups (nonsignificant). 27/37 controls not submitted to SIT did not report any change in symptom severity at the follow-up visits, whereas 10/37 reported a more severe disease (4 subjects reported the appearance of seasonal asthma) (p < 0.001 vs. patients submitted to SIT). Patients used less frequently cetirizine (p < 0.001) and/or salbutamol (p < 0.05) than controls not submitted to SIT. Conclusion: Injection SIT can be considered an effective therapeutic option in otherwise healthy elderly patients with a short disease duration whose symptoms cannot be adequately controlled by drug therapies alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Injection Immunotherapy with Ragweed and Birch Pollen in Elderly Patients

Asero¹

2004

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…These studies can be subdivided into 13 studies (5,7,9,11,12,15,17,19,22,32,35,36,39) investigating ragweed allergy (nine showing clinically relevant efficacy, i.e., symptom/medication scores diminished by >30% in the actively treated). Fifteen studies investigated the efficacy of immunotherapy in grass-pollen allergy (8,13,16,18,20,21,23,25,30,34,37,38,40,44,47), of which 14 proved efficacy. Nine studies investigated other pollen allergens: mountain cedar (10,27,29), Parietaria (42,43,46), Cupressus (45), Cocos (41), and mixtures (6); efficacy was demonstrated in six.…”

Section: Clinical Efficacy Of Immunotherapy In Rhinitismentioning

confidence: 99%

Immunotherapy as an effective tool in allergy treatment

Mailing¹

1998

Allergy

154

100

View full text Add to dashboard Cite

“…Allergoids are chemically altered confirmed on skin prick testing or with radioallergosorbent testing of serum (RAST). Trials involving allergen proteins which seem to be active in controlling symptoms 28 but have not yet been shown convincingly to sting challenge suggest that this treatment reduces the risk of anaphylaxis upon re-sting from around 50% to reduce side effects from treatment. Since many allergens have been cloned and IgE binding epitopes defined, it less than 5%.…”

Section: Other Modes Of Immunotherapymentioning

confidence: 99%

Allergen immunotherapy: does it work and, if so, how and for how long?

Robinson¹

2000

Thorax

View full text Add to dashboard Cite

Background. Pollen immunotherapy is effective in selected patients (median value in 1995, 2863). Although there was a tendency for immediate hypersensitivity to allergen to return late after discontinuation, there was sustained reduction in the late skin response and associated CD3+ T cell infiltration and interleukin-4 messenger RNA expression. Conclusions. Immunotherapy for grass pollen allergy for three to four years induces prolonged clinical remission accompanied by a persistent alteration in immunologic reactivity. (N Engl J Med 1999;341:468-75)

show abstract

Double-blind placebo-controlled immunotherapy with mixed grass-pollen allergoids

Cited by 156 publications

References 30 publications

Efficacy of Injection Immunotherapy with Ragweed and Birch Pollen in Elderly Patients

Efficacy of Injection Immunotherapy with Ragweed and Birch Pollen in Elderly Patients

Immunotherapy as an effective tool in allergy treatment

Allergen immunotherapy: does it work and, if so, how and for how long?

Contact Info

Product

Resources

About